Our Science – Yarchoan Website
Robert Yarchoan, M.D.
Selected Publications |
 |
| 1)
Venkataraman G, Uldrick TS, Aleman K, O'Mahony D, Karcher DS, Steinberg SM, Raffeld MA, Marshall V, Whitby D, Little RF, Yarchoan R, Pittaluga S, Maric I. Bone Marrow Findings in HIV-Positive Patients With Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. Am. J. Clin. Pathol. 139: 651-61, 2013. [Journal] |
|
| 2)
O'Mahony D, Little RF, Yarchoan R. LaFond RE, eds. AIDS and cancer. In: Cancer - The Outlaw Cell. New York: American Chemical Society and Oxford University Press USA; 2012. p. 165-178 [Book Chapter] |
|
| 3)
Sakakibara S, Espigol-Frigole G, Gasperini P, Uldrick TS, Yarchoan R, Tosato G. A20/TNFAIP3 inhibits NF-κB activation induced by the Kaposi's sarcoma-associated herpesvirus vFLIP oncoprotein. Oncogene. 32: 1223-32, 2012. [Journal] |
|
| 4)
Davis DA, Soule EE, Davidoff KS, Daniels SI, Naiman NE, Yarchoan R. Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing. Antimicrob. Agents Chemother. 56: 3620-8, 2012. [Journal] |
|
| 5)
Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome. Front Microbiol. 3: 73, 2012. [Journal] |
|
| 6)
Gasperini P, Espigol-Frigole G, McCormick PJ, Salvucci O, Maric D, Uldrick TS, Polizzotto MN, Yarchoan R, Tosato G. Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling. Cancer Res. 72: 1157-69, 2012. [Journal] |
|
| 7)
Abend JR, Ramalingam D, Kieffer-Kwon P, Uldrick TS, Yarchoan R, Ziegelbauer JM. Kaposi"s Sarcoma-Associated Herpesvirus MicroRNAs Target IRAK1 and MYD88, Two Components of the Toll-Like Receptor/Interleukin-1R Signaling Cascade, To Reduce Inflammatory-Cytokine Expression. J. Virol. 86: 11663-74, 2012. [Journal] |
|
| 8)
Veeranna RP, Haque M, Davis DA, Yang M, Yarchoan R. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induction by hypoxia and hypoxia-inducible factors. J. Virol. 86: 1097-108, 2012. [Journal] |
|
| 9)
Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R. Phase II Study of Bevacizumab in Patients With HIV-Associated Kaposi's Sarcoma Receiving Antiretroviral Therapy. J. Clin. Oncol. 30: 1476-83, 2012. [Journal] |
|
| 10)
Uldrick TS, Polizzotto MN, Yarchoan R. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr Opin Oncol. 24: 495-505, 2012. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 5/3/2013.
